Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 19/20 | 0.58 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL92251 | 0.90 | HIF1A (0.65) | HIF1ATP53SMN1; SMN2 | |
| SCHEMBL92212 | 0.88 | HIF1A (0.68) | HIF1ATP53 | |
| SCHEMBL10285797 | 0.87 | SMN1; SMN2 (0.48) | HIF1ATP53SMN1; SMN2 | |
| SCHEMBL92287 | 0.80 | SMN1; SMN2 (0.65) | HIF1ASMN1; SMN2 | |
| SCHEMBL14113772 | 0.80 | RAB9A (0.46) | HIF1ATP53SMN1; SMN2 | |
| SCHEMBL92200 | 0.79 | HIF1A (0.70) | HIF1A | |
| SCHEMBL92552 | 0.77 | KDM4E (0.53) | — | |
| SCHEMBL91547 | 0.77 | HIF1A (0.48) | HIF1ATP53SMN1; SMN2 | |
| SCHEMBL91565 | 0.77 | HIF1A (0.48) | HIF1ATP53SMN1; SMN2 | |
| SCHEMBL91597 | 0.77 | MAOB (0.57) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130065882-A1 | VLA-4 inhibitory drug | MACHINAGA NOBUO (JP) | 2013-03-14 | — | — | US | disclosed |
| US-20120157437-A1 | VLA-4 INHIBITORY DRUG | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-06-21 | — | — | US | disclosed |
| US-8129366-B2 | VLA-4 inhibitory drug | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-03-06 | — | — | US | disclosed |
| US-20090233901-A1 | VLA-4 INHIBITORY DRUG | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157437-A1 | VLA-4 INHIBITORY DRUG | VCAM1, ITGB4, ITGA4 | HIF1A 652/4885TP53 4440/4885SMN1; SMN2 4739/4885 |
| US-20130065882-A1 | VLA-4 inhibitory drug | VCAM1, ITGB4, ITGA4 | HIF1A 594/4885TP53 4330/4885SMN1; SMN2 4702/4885 |
| US-20090233901-A1 | VLA-4 INHIBITORY DRUG | VCAM1, ITGB4, ITGA4 | HIF1A 980/4885TP53 4578/4885SMN1; SMN2 4787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.